# Moderna

Type: Company (MRNA)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/moderna
Canonical HTML page: https://gethealthbrief.com/entity/moderna

## Timeline

- **2026-08-05**: FDA final decision deadline — The agency must decide whether to approve the first mRNA-based influenza vaccine, with major implications for the platform’s future.
- **2026-06**: Advisory panel recommends approval — The FDA’s Vaccines and Related Biological Products Advisory Committee votes to recommend the mRNA flu shot for licensure.
- **2026-02-18**: Regulatory U-Turn — The FDA officially agrees to consider the application after resolving the internal and public dispute.
- **2026-02-12**: Public Dispute — Reports emerge that career FDA scientists were overruled, leading to a public standoff between Moderna and the agency.
- **2026-02-05**: Initial Rejection — Trump administration vaccine chief refuses to review Moderna's mRNA flu shot application.
- **2026-02**: FDA refuses to review Moderna’s mRNA flu vaccine — FDA sends a refusal-to-file letter, stunning Moderna executives. Moderna had prior indications that a review would proceed.
- **2026-02**: FDA reverses decision after industry backlash — About a week later, FDA agrees to review the application after Moderna commits to a confirmatory post-market study, following public outcry and pressure.

## Recent coverage (7 stories)

### FDA's Aug. 5 decision on first mRNA flu shot could reshape $5B flu market
2026-08-01 14:59:02 · Sentiment: Neutral · Impact: 6/10 · Sources: 3

The FDA’s imminent decision on Moderna’s mRNA flu vaccine carries high stakes for healthcare providers and the vaccine industry. While an advisory panel backed approval, political skepticism from HHS Secretary RFK Jr. and a prior agency reversal add uncertainty. The ruling could either accelerate or stall mRNA’s expansion beyond COVID-19.
Full story: https://gethealthbrief.com/story/fda-mrna-flu-shot-health-regulation

### Federal Court Halts RFK Jr.’s Vaccine Policy Shift Amid Public Health Concerns
2026-03-21 00:47:44 · Sentiment: Neutral · Impact: 6/10 · Sources: 6

A federal judge has issued a temporary injunction against the vaccine policy agenda proposed by Robert F. Kennedy Jr., citing potential risks to public health infrastructure. While the ruling provides a reprieve for existing immunization standards, experts warn that the ongoing legal and political battle could further erode public confidence in scientific institutions.
Full story: https://gethealthbrief.com/story/federal-judge-blocks-rfk-jr-vaccine-agenda

### US Flu Vaccine Effectiveness Drops Below Historical Averages for 2025-26 Season
2026-03-14 23:47:43 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms.
Full story: https://gethealthbrief.com/story/flu-vaccine-effectiveness-decline-2026

### Post-Earnings Quant Ratings Reveal Sharp Divide in Healthcare Performance
2026-03-14 15:19:30 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Following the latest earnings cycle, Seeking Alpha's quantitative analysis identifies a significant performance gap between biopharma innovators and retail pharmacy giants. While Incyte and UnitedHealth lead with near-perfect scores, Walgreens and Moderna have fallen into 'Strong Sell' territory.
Full story: https://gethealthbrief.com/story/healthcare-quant-ratings-earnings-2026

### Moderna and SaaS Infrastructure Lead Broad Health-Tech Market Rally
2026-03-04 22:16:52 · Sentiment: Bullish · Impact: 6/10 · Sources: 5

A significant market rally on March 4, 2026, saw shares of Moderna, Wix, and Cloudflare surge as investors prioritized biotech innovation and the digital infrastructure powering modern healthcare delivery. These gains reflect a growing convergence between clinical breakthroughs and the secure, scalable platforms required to manage patient engagement at scale.
Full story: https://gethealthbrief.com/story/moderna-saas-infrastructure-health-tech-rally-2026

### Moderna Settles mRNA Patent Dispute with Roivant for Up to $2.25 Billion
2026-03-04 14:38:26 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Moderna has agreed to pay Roivant Sciences up to $2.25 billion to settle long-standing patent infringement claims regarding the Lipid Nanoparticle (LNP) technology used in its COVID-19 vaccine. The settlement provides a massive capital windfall for Roivant and Arbutus Biopharma while removing a major legal risk for Moderna.
Full story: https://gethealthbrief.com/story/moderna-roivant-mrna-patent-settlement

### FDA Reverses Course on Moderna mRNA Flu Shot Following Public Dispute
2026-02-19 09:53:59 · Sentiment: Bullish · Impact: 8/10 · Sources: 13

The FDA has agreed to review Moderna’s mRNA-based influenza vaccine after a high-profile rejection by the Trump administration's vaccine chief. The reversal follows a public dispute where scientific staff were reportedly overruled, marking a significant shift for the first-of-its-kind vaccine candidate.
Full story: https://gethealthbrief.com/story/fda-moderna-flu-shot-reversal

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.